Eli Lilly's $83 Billion Forecast Cements Its Reign as the Undisputed King of the Weight-Loss Drug Revolution
Eli Lilly posted blowout Q4 2025 earnings and issued 2026 revenue guidance of $80 to $83 billion, crushing Wall Street expectations as Mounjaro and Zepbound sales soar past $11.6 billion in a single quarter.